Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease

IDrugs

Volumn 12, Issue 9, 2009, Pages 585-592

  Karakas, Mahir ^a   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

A 002; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LY 333013; PHOSPHOLIPASE A2; PLACEBO; S 3013; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; VARESPLADIB;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INHIBITION; HEADACHE; HUMAN; INFLAMMATION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; ULCERATIVE COLITIS;

ACETATES; ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CORONARY ARTERY DISEASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; INDOLES; PATENTS AS TOPIC; PHOSPHOLIPASES A2, SECRETORY; PRODRUGS;

EID: 69249088914     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 2. 1. indole-3-acetamides. Dillard RD, Bach NJ, Draheim SE, Berry DR, Carlson DG, Chirgadze NY, Clawson DK, Hartley LW, Johnson LM, Jones ND, McKinney ER et al J MED CHEM 1996 39 26 5119-5136
2. 247025 Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. indole-3-acetamides with additional functionality. Dillard RD, Bach NJ, Draheim SE, Berry DR, Carlson DG, Chirgadze NY, Clawson DK, Hartley LW, Johnson LM, Jones ND, McKinney ER et al J MED CHEM 1996 39 26 5137-5158
3. 2. 3. indole-3-glyoxamides. Draheim SE, Bach NJ, Dillard RD, Berry DR, Carlson DG, Chirgadze NY, Clawson DK, Hartley LW, Johnson LM, Jones ND, McKinney ER et al J MED CHEM 1996 39 26 5159-5175
4. 2 inhibitor S-5920-/LY-315920Na Kenji K, Kazushige T, Shingo F, Takashi O, Yozo H INFLAMM RES 1997 46 Suppl 3 S-238
5. 437753 Safety and efficacy of an sPLA2 inhibitor in treating ulcerative colitis. Lashner B, Korzenik J, Dmitrienko A, Hunt R, Myers S, Krueger K AM J GASTROENTEROL 2001 96 9 S297
6. 2 enzymes in the arterial wall during atherogenesis.
7. 488178 Annual report 2002: Shionogi & Co Ltd. Shionogi & Co Ltd ANNUAL REPORT 2002 March 31
8. 593986 Form 10-K 2004 Eli Lilly & Co. Eli Lilly & Co FORM 10-K 2005 March 01
9. 595207 Company website: Shionogi. Shionogi & Co Ltd COMPANY WORLD WIDE WEB SITE 2005 January 31
10. 688686 Anthera licenses portfolio of anti-inflammatory products from Eli Lilly and Company and Shionogi & Co, Ltd. Anthera Pharmaceuticals Inc PRESS RELEASE 2006 September 06
11. 783686 First patient enrolled in phase 2 'PLASMA' trial with A-002 for patients with coronary atherosclerosis. Anthera Pharmaceuticals Inc PRESS RELEASE 2007 April 13
12. 805618 Prevention of atherosclerosis by sPLA2 inhibitor in a mouse model. Trias J, Fraser H, Hislop C WORLD CONGR INFLAMM 2007 8 June 19 Abs FG05.6
13. 812018 Role of group IIA phospholipase A2 in rat colitis induced by dextran sulfate sodium. Tomita Y, Jyoyama H, Kobayashi M, Kuwabara K, Furue S, Ueno M, Yamada K, Ono T, Teshirogi I, Nomura K, Arita H et al EUR J PHARMACOL 2003 472 1-2 147-158
14. 872442 Anthera enters into manufacturing agreements for varespladib in preparation for pivotal phase III trials. Anthera Pharmaceuticals Inc PRESS RELEASE 2008 January 31
15. 874396 Anthera enters into manufacturing agreements for varespladib in preparation for pivotal phase III trials. Anthera Pharmaceuticals Inc PRESS RELEAASE 2008 February 05
16. 2 inhibitor varespladib (A-002). Shaposhnik Z, Wang XP, Trias J, Fraser H, Lusis A ARTERIOSCLER THROMB VASC BIOL 2008 28 6 E53
17. 920391 Anthera Pharmaceuticals website Anthera Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2008 June 26
18. 945755 Anthera completes special protocol assessment with FDA and receives EMEA scientific advice on development path toward varespladib approval. Anthera Pharmaceuticals Inc PRESS RELEASE 2008 September 24
19. 2 on low density and very low density lipoprotein subclasses in stable coronary heart disease patients. Rosenson RS, Hislop C, Elliott M, Stasiv Y AM HEART ASSOC SCIENTIFIC SESSIONS 2008 S406-S407 Abs 1928
20. 975755 Anthera completes enrollment and dosing of varespladib cardiovascular trial. Anthera Pharmaceuticals Inc PRESS RELEASE 2009 January 12
21. -/- mice fed a high-fat diet. Similarly, in an accelerated atherosclerosis model, varespladib methyl reduced aortic atherosclerosis and attenuated aneurysm formation.
22. 2 IIA and LDL-cholesterol concentrations decreased significantly in the treatment groups compared with the placebo group.
23. 2 on atherogenic lipoproteins in stable coronary heart disease patients with and without diabetes. Rosenson RS, Bittman RM, Hislop C J AM COLL CARDIOL 2009 53 10, Suppl 1 Abs 1021-70
24. 2 inhibitor varespladib (A-002). Shaposhnik Z, Wang X, Trias J, Fraser H, Lusis AJ J LIPID RES 2009 50 4 623-629 **Presents results from a study assessing varespladib methyl and pravastatin as monotherapies and in combination in ApoE-/- mice. Varespladib methyl significantly reduced atherosclerotic lesion formation, whereas pravastatin monotherapy had no effect on the size of atherosclerotic lesions. A synergetic decrease in lesion size was observed when pravastatin was combined with varespladib methyl.
25. 2 inhibitor, reduces atherosclerosis in guinea pigs. Leite JO, Vaishnav U, Puglisi M, Fraser H, Trias J, Fernandez ML BMC CARDIOVASC DISORD 2009 9 7 1-9
26. 1006587 Anthera's varespladib meets primary endpoint in phase 2 FRANCIS trial for the treatment of acute coronary syndrome. Anthera Pharmaceuticals Inc PRESS RELEASE 2009 May 06
27. 2. Andreani M, Olivier JL, Berenbaum F, Raymondjean M, Bereziat G BIOCHIM BIOPHYS ACTA MOL CELL BIOL LIPIDS 2000 1488 1-2 149-158
28. 2, and the risk of coronary heart disease.
29. 1019532 Interferon-γ induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E J BIOL CHEM 2000 275 30 22895-22904
30. 2 in human monocyte-derived macrophages. Anthonsen MW, Stengel D, Hourton D, Ninio E, Johansen B ARTERIOSCLER THROMB VASC BIOL 2000 20 5 1276-1282
31. 2 in normal and atherosclerotic arteries Activity of the isolated enzyme on low-density lipoproteins. Hurt Camejo E, Andersen S, Standal R, Rosengren B, Sartipy P, Stadberg E, Johansen B ARTERIOSCLER THROMB VASC BIOL 1997 17 2 300-309
32. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Hakala JK, Oorni K, Pentikainen MO, Hurt-Camejo E, Kovanen PT ARTERIOSCLER THROMB VASC BIOL 2001 21 6 1053-1058
33. 2 by rat mesangial cells Its contribution to arachidonic-acid release and prostaglandin synthesis by cultured rat glomerular cells. Pfeilschifter J, Shalkwijk C, Briner VA, van den Bosch H J CLIN INVEST 1993 92 5 2516-2523
34. 1019546 Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells Evidence for release of fibroblast growth factor-2. Chai YC, Howe PH, DiCorleto PE, Chisolm GM J BIOL CHEM 1996 271 30 17791-17797
35. 2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells. Anderson KM, Roshak A, Winkler JD, McCord M, Marshall LA J BIOL CHEM 1998 272 48 30504-30511
36. 2, in the treatment of rheumatoid arthritis. Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD J RHEUMATOL 2005 32 3 417-423
37. 2 inhibitor on inhaled allergen challenge in subjects with asthma. Bowton DL, Dmitrienko AA, Israel E, Zeiher BG, Sides GD J ASTHMA 2005 42 1 65-71
38. 1019558 Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ J AM COLL CARDIOL 2004 44 3 720-732
39. 1019560 Mechanisms of disease Inflammation, atherosclerosis, and coronary artery disease. Hansson GK N ENGL J MED 2005 352 16 1685-1695
40. 1024018 Dynamics of cardiovascular and all-cause mortality in western and eastern europe between 1970 and 2000. Kesteloot H, Sans S, Kromhout D EUR HEART J 2006 27 1 107-113
41. 1024020 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A et al EUR HEART J 2008 29 19 2388-2442
42. 2. Boyanovsky BB, Webb NR CARDIOVASC DRUGS THER 2009 23 1 61-72
43. 1024077 Role of secretory phospholipases in atherogenesis. Jonsson-Rylander AC, Lundin S, Rosengren B, Pettersson C, Hurt-Camejo E CURR ATHEROSCLEROSIS REP 2008 10 3 252-259
44. 2 inhibitor: A new class of anti-inflammatory drugs, SPI. Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM et al J PHARMACOL EXP THER 1999 288 3 1117-1124
45. 1024169 Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S LANCET 2006 368 9535 581-588
46. 1024170 The forgotten majority: Unfinished business in cardiovascular risk reduction. Libby P J AM COLL CARDIOL 2005 46 7 1225-1228
47. 1024536 European cardiovascular disease statistics 2008 edition. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A INTERNET SITE 2007 Nov 30
48. 1024834 Relative oral bioavailability of LY315920 in male cynomolgus monkeys following a single 10 mg/kg oral dose of LY315920-sodium or LY333013. Rowe JM, Farid NA, Glass SJ, -Pohland RC AAPS PHARMSCI 2003 5 S1 Abs 1668
49. 2 activity and risk of incident coronary events in healthy men and women The EPIC-Norfolk study. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A et al ARTERIOSCLER THROMB VASC BIOL 2007 27 5 1177-1183
50. 2-dependent lipid peroxidation. Luchtefeld M, Bandlow N, Tietge UJF, Grote K, Pfeilschifter J, Kaszkin M, Beck S, Drexler H, Schieffer B ATHEROSCLEROSIS 2007 194 62-70